Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain ...

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

Convatec announced that it received FDA approval for the delivery of a Parkinson's disease therapy through its Neria Guard ...

Medication aside, there are many ways people living with Parkinson’s disease can improve their health and well-being, preserve physical function, ease symptoms and enhance quality of life. Chief among ...

Existing drugs could be reused to treat Alzheimer’s and Parkinson’s Scientists say there are ‘commonalities’ between the diseases which mean some drugs may work for both ...

Discover how ear wax analysis could revolutionize early Parkinson's detection with a non-invasive, accurate diagnostic method.

The company is planning a double-blind, placebo-controlled Phase 2 trial in Parkinson’s disease and potentially in Alzheimer’s disease. Ventyx is also studying VTX3232 in a 12-week Phase 2 trial for ...

Ventyx Biosciences (VTYX) stock slips even as the company's Parkinson’s therapy VTX3232 shows promise in a Phase 2a trial. Read more here.

It delivers a continuous subcutaneous infusion of levodopa-carbidopa—the gold-standard medication for Parkinson’s—through a compact pump connected to the skin.

Notably, all patients in the advanced stages of Parkinson’s are eligible for it. It delivers a continuous subcutaneous infusion of levodopa-carbidopa—the gold-standard medication for ...